Pascal and Francis Bibliographic Databases


Search results

Your search

au.\*:("Christopher, Paul")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 68

  • Page / 3

Selection :

  • and

The exposome: from concept to utilityWILD, Christopher Paul.International journal of epidemiology. 2012, Vol 41, Num 1, pp 24-32, issn 0300-5771, 9 p.Article

Paediatric assessment : An essential part of standard drug developmentMILNE, Christopher-Paul.International journal of pharmaceutical medicine. 2006, Vol 20, Num 5, pp 297-301, issn 1364-9027, 5 p.Article

Orphan products-pain relief for clinical development headaches: As the cost of clinical development rises, and products take longer to reach the market, the biotechnology industry may be wise to take a closer look at orphan drug indicationsMILNE, Christopher-Paul.Nature biotechnology. 2002, Vol 20, Num 8, pp 780-784, issn 1087-0156, 5 p.Article

The single controlled trial: Industry survey indicates that implementation is still a work in progressMILNE, Christopher-Paul.Drug information journal. 2002, Vol 36, Num 2, pp 291-302, issn 0092-8615, 12 p.Article

Fast track product designation under the food and drug administration modernization ACT: The industry experienceMILNE, Christopher-Paul; BERGMAN, Elaine.Drug information journal. 2001, Vol 35, Num 1, pp 71-83, issn 0092-8615Article

The Pediatric Studies Initiative: After 15 Years Have We Reached the Limits of the Law? : PEDIATRIC CLINICAL TRIALS AND DRUG DEVELOPMENTMILNE, Christopher-Paul; DAVIS, Jonathan.Clinical therapeutics. 2014, Vol 36, Num 2, pp 156-162, issn 0149-2918, 7 p.Article

The cost and value of new medicines in an era of change: partial proceedings of a symposium, Talloires, France, 25-27 July, 2001MILNE, Christopher-Paul; LASAGNA, Louis.PharmacoEconomics (Auckland). 2002, Vol 20, issn 1170-7690, 118 p., SUP3Conference Proceedings

A new view of millimeter-wave satellite communicationCHRISTOPHER, Paul.IEEE antennas & propagation magazine. 2002, Vol 44, Num 2, pp 59-61, issn 1045-9243Article

Meeting the challenges to European healthcare. Lessons learned from the 'Stockholm Revolution'HJERTQVIST, Johan.PharmacoEconomics (Auckland). 2002, Vol 20, pp 47-53, issn 1170-7690, 7 p., SUP3Conference Paper

The prospects for reform of the Japanese healthcare systemTOKITA, Tadahiko.PharmacoEconomics (Auckland). 2002, Vol 20, pp 55-66, issn 1170-7690, 12 p., SUP3Conference Paper

Fixing the paradigm for biopharmaceutical R&D : Where to start?MILNE, Christopher-Paul.International journal of biotechnology. 2008, Vol 10, Num 5, pp 404-415, issn 0963-6048, 12 p.Article

Benefits of lifestyle modification in NAFLDHARRISON, Stephen A; DAY, Christopher Paul.Gut. 2007, Vol 56, Num 12, pp 1760-1769, issn 0017-5749, 10 p.Article

The Economics of Pediatric Formulation Development for Off-Patent DrugsMILNE, Christopher-Paul; BRUSS, Jon B.Clinical therapeutics. 2008, Vol 30, Num 11, pp 2133-2145, issn 0149-2918, 13 p.Conference Paper

Balancing the cost and value of medications. The dilemma facing cliniciansAVORN, Jerry.PharmacoEconomics (Auckland). 2002, Vol 20, pp 67-72, issn 1170-7690, 6 p., SUP3Conference Paper

Current and Future Therapeutic Strategies in NAFLD : Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosisDE ALWIS, Nimantha Mark Wilfred; DAY, Christopher Paul.Current pharmaceutical design (Print). 2010, Vol 16, Num 17, pp 1958-1962, issn 1381-6128, 5 p.Article

Concluding remarksLASAGNA, Louis.PharmacoEconomics (Auckland). 2002, Vol 20, pp 107-108, issn 1170-7690, 2 p., SUP3Conference Paper

Reimbursement and cost containment. A German perspectiveBREYER, Friedrich.PharmacoEconomics (Auckland). 2002, Vol 20, pp 87-94, issn 1170-7690, 8 p., SUP3Conference Paper

A profile of the health sector in the United StatesTURNER, Grace-Marie.PharmacoEconomics (Auckland). 2002, Vol 20, pp 31-45, issn 1170-7690, 15 p., SUP3Conference Paper

Effect of mercury and Gpi-2 genotype on standard metabolic rate of eastern mosquitofish (gambusia holbrooki)TATARA, Christopher Paul; NEWMAN, Michael C; MULVEY, Margaret et al.Environmental toxicology and chemistry. 2001, Vol 20, Num 4, pp 782-786, issn 0730-7268Article

Genetic and demographic responses of mercury-exposed mosquitofish (Gambusia holbrooki) populations: Temporal stability and reproductive components of fitnessTATARA, Christopher Paul; MULVEY, Margaret; NEWMAN, Michael C et al.Environmental toxicology and chemistry. 2002, Vol 21, Num 10, pp 2191-2197, issn 0730-7268Article

The role of marketing in pharmaceutical research and developmentCALFEE, John E.PharmacoEconomics (Auckland). 2002, Vol 20, pp 77-85, issn 1170-7690, 9 p., SUP3Conference Paper

The value of improving the productivity of the drug development process. Faster times and better decisionsDIMASI, Joseph A.PharmacoEconomics (Auckland). 2002, Vol 20, pp 1-10, issn 1170-7690, 10 p., SUP3Conference Paper

The Ågrenska centre: A socioeconomic case study of rare diseasesOLAUSON, Anders.PharmacoEconomics (Auckland). 2002, Vol 20, pp 73-75, issn 1170-7690, 3 p., SUP3Conference Paper

Wideband channelized receiver possibilities with 0.18 micron CMOS technologyMCWILLIAMS, J. K; WENTZEL, S. W.SPIE proceedings series. 1998, pp 44-49, isbn 0-8194-2665-2Conference Paper

Measurement of scintillation and link margin for the TerraLink<TM> laser communication systemKIM, I. I; KOONTZ, J; KOREVAAR, E et al.SPIE proceedings series. 1998, pp 100-118, isbn 0-8194-2665-2Conference Paper

  • Page / 3